Heartflow Q3 Results – 13 Nov 2026
Heartflow, Inc. (NASDAQ:HTFL) announced third‑quarter 2026 financial results that surpassed analyst expectations. The company posted adjusted earnings of a loss of $0.03 per share, considerably better than the consensus forecast of a $0.17 loss per share. Total revenue for the quarter reached $72.9 million, representing a 57% year‑over‑year increase from $46.3 million in the comparable period of the prior year.
U.S. revenue accelerated 60% YoY to $67.9 million, while international revenue grew 29% YoY to $4.9 million. Adjusted gross margin improved to 83.8%, up from 76.8% in the same quarter last year, reflecting higher case volumes and productivity gains from AI‑driven efficiency initiatives. The adjusted operating loss narrowed sharply to $5.0 million, compared with $11.1 million in Q3 2025.
The firm raised its full‑year 2026 revenue guidance to a range of $262 million‑$264 million, implying 49%‑50% growth YoY, up from the prior outlook of $246 million‑$250 million. Correspondingly, the adjusted gross‑margin target was increased to approximately 82.5% from the earlier 82% guidance.
Cash, cash equivalents and investments stood at $253.0 million as of 30 September 2026. Despite the positive earnings beat and upgraded guidance, the market reacted negatively, with Heartflow shares declining 5% immediately after the earnings release.
"Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters," said John Farquhar, President and CEO of Heartflow. "Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again."